Imatinib

Oncologist

Volumn 12, Issue 12, 2007, Pages 1390-1394

  De Kogel, Christine E ^a   Schellens, Jan H M ^a,b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BREAST CANCER RESISTANCE PROTEIN; CYCLOSPORIN; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; ERYTHROMYCIN; HYPERICUM PERFORATUM EXTRACT; IMATINIB; KETOCONAZOLE; MULTIDRUG RESISTANCE PROTEIN 1; OROSOMUCOID; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RIFAMPICIN; SIMVASTATIN;

BONE MARROW TOXICITY; CHRONIC MYELOID LEUKEMIA; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; EDEMA; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LIVER DYSFUNCTION; MUSCLE CRAMP; NAUSEA; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; VOMITING;

ADULT; ANTINEOPLASTIC AGENTS; CHILD; DRUG RESISTANCE, NEOPLASM; HUMANS; PIPERAZINES; PYRIMIDINES;

EID: 38049047565     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-12-1390     Document Type: Review

References (13)

1. Druker BJ, Guilhot F, O'Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417.
2. Capdeville R, Buchdunger E, Zimmerman J et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002;1:493-502.
3. Desjardins A, Quinn JA, Vredenburgh JJ et al. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol 2007;83:53-60.
4. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukaemia. Blood 2005;105:2640-2653.
5. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005;44:879-894.
6. Titier K, Picard S, Ducint D et al. Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Ther Drug Monit 2005;27:634-640.
7. Gardner ER, Burger H, van Schaik RH et al. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther 2006;80:192-201.
8. Gurney H, Wong M, Balleine RL et al. Imatinib disposition and ABCB1 (MDR-1, P-glycoprotein) genotype. Clin Pharmacol Ther 2007;82:33-40.
9. Hochhaus A, Kreil S, Corbin AS et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16:2190-2196.
10. Villuendas R, Steegmann JL, Pollàn M et al. Identification of genes involved in imatinib resistance in CML: A gene-expression profiling approach. Leukemia 2006;20:1047-1054.
11. Heinrich MC, Corless CL, Blanke CD et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006;24:4764-4774.
12. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004;364:1127-1134.
13. Massagué J. G1 cell-cycle control and cancer. Nature 2004;432:298-306.